Wockhardt LimitedNSE: WOCKPHARMA

Press Release Jan 07 2026

· Issued by Wockhardt Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

The application is eligible for Accelerated Assessment due to the urgent medical need it addresses, particularly for resistant Gram-negative infections. The drug has also been submitted for review by the US FDA and has completed pivotal clinical trials.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Wockhardt Limited on 6ix

Earlier from Wockhardt

Later from Wockhardt

All Wockhardt news releases